Verastem Inc (VSTM) Upgraded to Buy at Zacks Investment Research

Paterniano Del Favero
Luglio 17, 2017

According to the analysts, Verastem Inc (NASDAQ:VSTM) is expected to announce $-0.34/share EPS for the current quarter. Ltd.'s portfolio, making the stock its largest position.

Several other research firms have also recently issued reports on VSTM. Fmr Lc owns 0% invested in Verastem Inc (NASDAQ:VSTM) for 901,200 shares. The stock has gained 2.00%, reaching at $4.09 after hovering between $3.82 and $4.67. Renaissance Technologies LLC boosted its stake in shares of Verastem by 13.6% in the fourth quarter. The institutional investor owned 373,420 shares of the biopharmaceutical company's stock after selling 700 shares during the period. Verastem Inc (NASDAQ:VSTM)'s price to free cash flow for trailing twelve months is 0. The stock's market capitalization is $148.34 million. The stock's 50-day moving average is $2.25 and its 200-day moving average is $1.66.

Verastem (NASDAQ:VSTM) last issued its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35). On average, equities research analysts anticipate that Verastem will post ($1.31) EPS for the current year.

ILLEGAL ACTIVITY WARNING: "Verastem Inc (NASDAQ:VSTM) Stake Held by Deer VII & Co. Ltd." was first published by Stock Observer and is the property of of Stock Observer. If you are accessing this piece of content on another publication, it was stolen and republished in violation of USA & global copyright & trademark legislation. It is meant to chart the current and historical strength or weakness of a stock or market based on the closing prices of a recent trading period. It is positive, as 6 investors sold Verastem Inc shares while 15 reduced holdings.

Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $4.38 on the stock, this valuation is based on 4 number of opinions. Cantor Fitzgerald reiterated a "hold" rating and issued a $2.00 target price on shares of Verastem in a research note on Thursday, May 11th. Jefferies Group LLC reiterated a "hold" rating and set a $1.50 target price on shares of Verastem in a research report on Wednesday, June 28th. HC Wainwright lifted their target price on shares of Verastem from $5.00 to $6.50 and gave the company a "buy" rating in a research report on Friday, March 24th. Oppenheimer maintained the stock with "Buy" rating in Wednesday, July 12 report. The company now has an average rating of "Buy" and an average target price of $4.54.

In other Verastem news, Director Timothy J. Barberich purchased 30,000 shares of the firm's stock in a transaction on Monday, May 15th. The stock was acquired at an average cost of $2.45 per share, for a total transaction of $73,500.00. Following the acquisition, the director now owns 69,462 shares in the company, valued at approximately $170,181.90. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Verastem, Inc is a biopharmaceutical company.

Altre relazioni OverNewsmagazine

Discuti questo articolo